Literature DB >> 33239457

The Human Adenovirus Type 2 Transcriptome: An Amazing Complexity of Alternatively Spliced mRNAs.

Amanda Westergren Jakobsson1,2, Bo Segerman1,3, Ola Wallerman1, Sara Bergström Lind4, Hongxing Zhao2, Carl-Johan Rubin1, Ulf Pettersson2, Göran Akusjärvi5.   

Abstract

We have used the Nanopore long-read sequencing platform to demonstrate how amazingly complex the human adenovirus type 2 (Ad2) transcriptome is with a flexible splicing machinery producing a range of novel mRNAs both from the early and late transcription units. In total we report more than 900 alternatively spliced mRNAs produced from the Ad2 transcriptome whereof more than 850 are novel mRNAs. A surprising finding was that more than 50% of all E1A transcripts extended upstream of the previously defined transcriptional start site. The novel start sites mapped close to the inverted terminal repeat (ITR) and within the E1A enhancer region. We speculate that novel promoters or enhancer driven transcription, so-called eRNA transcription, is responsible for producing these novel mRNAs. Their existence was verified by a peptide in the Ad2 proteome that was unique for the E1A ITR mRNA. Although we show a high complexity of alternative splicing from most early and late regions, the E3 region was by far the most complex when expressed at late times of infection. More than 400 alternatively spliced mRNAs were observed in this region alone. These mRNAs included extended L4 mRNAs containing E3 and L5 sequences and readthrough mRNAs combining E3 and L5 sequences. Our findings demonstrate that the virus has a remarkable capacity to produce novel exon combinations, which will offer the virus an evolutionary advantage to change the gene expression repertoire and protein production in an evolving environment.IMPORTANCE Work in the adenovirus system led to the groundbreaking discovery of RNA splicing and alternative RNA splicing in 1977. These mechanisms are essential in mammalian evolution by increasing the coding capacity of a genome. Here, we have used a long-read sequencing technology to characterize the complexity of human adenovirus pre-mRNA splicing in detail. It is mindboggling that the viral genome, which only houses around 36,000 bp, not being much larger than a single cellular gene, generates more than 900 alternatively spliced mRNAs. Recently, adenoviruses have been used as the backbone in several promising SARS-CoV-2 vaccines. Further improvement of adenovirus-based vaccines demands that the virus can be tamed into an innocent carrier of foreign genes. This requires a full understanding of the components that govern adenovirus replication and gene expression.
Copyright © 2020 Westergren Jakobsson et al.

Entities:  

Year:  2020        PMID: 33239457      PMCID: PMC7851563          DOI: 10.1128/JVI.01869-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Adenovirus assay by the fluorescent cell-counting procedure.

Authors:  L PHILIPSON
Journal:  Virology       Date:  1961-11       Impact factor: 3.616

2.  A map of cytoplasmic RNA transcripts from lytic adenovirus type 2, determined by electron microscopy of RNA:DNA hybrids.

Authors:  L T Chow; J M Roberts; J B Lewis; T R Broker
Journal:  Cell       Date:  1977-08       Impact factor: 41.582

3.  Identification of the adenovirus type 2 C-168 protein.

Authors:  Arina Gromova; Hongxing Zhao; Anne Konzer; Alexander Falk; Ulf Pettersson; Sara Bergström Lind
Journal:  Virus Res       Date:  2017-06-16       Impact factor: 3.303

4.  L4-33K, an adenovirus-encoded alternative RNA splicing factor.

Authors:  Heidi Törmänen; Ellenor Backström; Anette Carlsson; Göran Akusjärvi
Journal:  J Biol Chem       Date:  2006-10-06       Impact factor: 5.157

Review 5.  Lessons learned from adenovirus (1970-2019).

Authors:  Glen Nemerow; Jane Flint
Journal:  FEBS Lett       Date:  2019-12-20       Impact factor: 4.124

6.  The 2.2 kb E1b mRNA of human Ad12 and Ad5 codes for two tumor antigens starting at different AUG triplets.

Authors:  J L Bos; L J Polder; R Bernards; P I Schrier; P J van den Elsen; A J van der Eb; H van Ormondt
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

7.  An adenovirus agnogene.

Authors:  A Virtanen; P Aleström; H Persson; M G Katze; U Pettersson
Journal:  Nucleic Acids Res       Date:  1982-04-24       Impact factor: 16.971

Review 8.  Enhancer-derived RNA: A Primer.

Authors:  Feng Liu
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-05-19       Impact factor: 7.691

9.  TopHat: discovering splice junctions with RNA-Seq.

Authors:  Cole Trapnell; Lior Pachter; Steven L Salzberg
Journal:  Bioinformatics       Date:  2009-03-16       Impact factor: 6.937

10.  ProteomeXchange provides globally coordinated proteomics data submission and dissemination.

Authors:  Juan A Vizcaíno; Eric W Deutsch; Rui Wang; Attila Csordas; Florian Reisinger; Daniel Ríos; José A Dianes; Zhi Sun; Terry Farrah; Nuno Bandeira; Pierre-Alain Binz; Ioannis Xenarios; Martin Eisenacher; Gerhard Mayer; Laurent Gatto; Alex Campos; Robert J Chalkley; Hans-Joachim Kraus; Juan Pablo Albar; Salvador Martinez-Bartolomé; Rolf Apweiler; Gilbert S Omenn; Lennart Martens; Andrew R Jones; Henning Hermjakob
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

View more
  2 in total

Review 1.  Nanopore sequencing technology and its application in plant virus diagnostics.

Authors:  Kai Sun; Yi Liu; Xin Zhou; Chuanlin Yin; Pengjun Zhang; Qianqian Yang; Lingfeng Mao; Xuping Shentu; Xiaoping Yu
Journal:  Front Microbiol       Date:  2022-07-25       Impact factor: 6.064

2.  Novel viral splicing events and open reading frames revealed by long-read direct RNA sequencing of adenovirus transcripts.

Authors:  Alexander M Price; Robert T Steinbock; Richard Lauman; Matthew Charman; Katharina E Hayer; Namrata Kumar; Edwin Halko; Krystal K Lum; Monica Wei; Angus C Wilson; Benjamin A Garcia; Daniel P Depledge; Matthew D Weitzman
Journal:  PLoS Pathog       Date:  2022-09-12       Impact factor: 7.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.